Medical Care
Global Large Molecule Drug Substance CDMO Market Research Report 2026
- Feb 24, 26
- ID: 695888
- Pages: 134
- Figures: 140
- Views: 13
This report delivers a comprehensive overview of the global Large Molecule Drug Substance CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Large Molecule Drug Substance CDMO. The Large Molecule Drug Substance CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Large Molecule Drug Substance CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Large Molecule Drug Substance CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Segment by Type
Cell and Gene Therapies
Antibodies
Vaccines
Other
Segment by Application
SMBs
Large Companies
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Large Molecule Drug Substance CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
The report segments the global Large Molecule Drug Substance CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Large Molecule Drug Substance CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi Biologics
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Segment by Type
Cell and Gene Therapies
Antibodies
Vaccines
Other
Segment by Application
SMBs
Large Companies
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Large Molecule Drug Substance CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 Market by Application
1.3.1 Global Large Molecule Drug Substance CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Large Molecule Drug Substance CDMO Market Perspective (2021–2032)
2.2 Global Large Molecule Drug Substance CDMO Growth Trends by Region
2.2.1 Global Large Molecule Drug Substance CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Large Molecule Drug Substance CDMO Historic Market Size by Region (2021–2026)
2.2.3 Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2027–2032)
2.3 Large Molecule Drug Substance CDMO Market Dynamics
2.3.1 Large Molecule Drug Substance CDMO Industry Trends
2.3.2 Large Molecule Drug Substance CDMO Market Drivers
2.3.3 Large Molecule Drug Substance CDMO Market Challenges
2.3.4 Large Molecule Drug Substance CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue
3.1.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue (2021–2026)
3.1.2 Global Large Molecule Drug Substance CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Large Molecule Drug Substance CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Large Molecule Drug Substance CDMO Revenue
3.4 Global Large Molecule Drug Substance CDMO Market Concentration Ratio
3.4.1 Global Large Molecule Drug Substance CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Large Molecule Drug Substance CDMO Revenue in 2025
3.5 Global Key Players of Large Molecule Drug Substance CDMO Head Offices and Areas Served
3.6 Global Key Players of Large Molecule Drug Substance CDMO, Products and Applications
3.7 Global Key Players of Large Molecule Drug Substance CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Large Molecule Drug Substance CDMO Breakdown Data by Type
4.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Type (2021–2026)
4.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2027–2032)
5 Large Molecule Drug Substance CDMO Breakdown Data by Application
5.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Application (2021–2026)
5.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Large Molecule Drug Substance CDMO Market Size (2021–2032)
6.2 North America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
6.4 North America Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Large Molecule Drug Substance CDMO Market Size (2021–2032)
7.2 Europe Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
7.4 Europe Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Large Molecule Drug Substance CDMO Market Size (2021–2032)
8.2 Asia-Pacific Large Molecule Drug Substance CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Large Molecule Drug Substance CDMO Market Size (2021–2032)
9.2 Latin America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
9.4 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Large Molecule Drug Substance CDMO Market Size (2021–2032)
10.2 Middle East & Africa Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Large Molecule Drug Substance CDMO Introduction
11.1.4 Lonza Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Large Molecule Drug Substance CDMO Introduction
11.2.4 Catalent Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Large Molecule Drug Substance CDMO Introduction
11.3.4 Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Large Molecule Drug Substance CDMO Introduction
11.5.4 Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi Biologics
11.6.1 WuXi Biologics Company Details
11.6.2 WuXi Biologics Business Overview
11.6.3 WuXi Biologics Large Molecule Drug Substance CDMO Introduction
11.6.4 WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.6.5 WuXi Biologics Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Large Molecule Drug Substance CDMO Introduction
11.7.4 Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Large Molecule Drug Substance CDMO Introduction
11.8.4 Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Large Molecule Drug Substance CDMO Introduction
11.9.4 AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Large Molecule Drug Substance CDMO Introduction
11.10.4 Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Large Molecule Drug Substance CDMO Introduction
11.11.4 KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Large Molecule Drug Substance CDMO Introduction
11.12.4 Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Large Molecule Drug Substance CDMO Introduction
11.13.4 Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Large Molecule Drug Substance CDMO Introduction
11.14.4 GenScript Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Large Molecule Drug Substance CDMO Introduction
11.15.4 ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Large Molecule Drug Substance CDMO Introduction
11.16.4 Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Introduction
11.17.4 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 Market by Application
1.3.1 Global Large Molecule Drug Substance CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Large Molecule Drug Substance CDMO Market Perspective (2021–2032)
2.2 Global Large Molecule Drug Substance CDMO Growth Trends by Region
2.2.1 Global Large Molecule Drug Substance CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Large Molecule Drug Substance CDMO Historic Market Size by Region (2021–2026)
2.2.3 Large Molecule Drug Substance CDMO Forecasted Market Size by Region (2027–2032)
2.3 Large Molecule Drug Substance CDMO Market Dynamics
2.3.1 Large Molecule Drug Substance CDMO Industry Trends
2.3.2 Large Molecule Drug Substance CDMO Market Drivers
2.3.3 Large Molecule Drug Substance CDMO Market Challenges
2.3.4 Large Molecule Drug Substance CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue
3.1.1 Global Top Large Molecule Drug Substance CDMO Players by Revenue (2021–2026)
3.1.2 Global Large Molecule Drug Substance CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Large Molecule Drug Substance CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Large Molecule Drug Substance CDMO Revenue
3.4 Global Large Molecule Drug Substance CDMO Market Concentration Ratio
3.4.1 Global Large Molecule Drug Substance CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Large Molecule Drug Substance CDMO Revenue in 2025
3.5 Global Key Players of Large Molecule Drug Substance CDMO Head Offices and Areas Served
3.6 Global Key Players of Large Molecule Drug Substance CDMO, Products and Applications
3.7 Global Key Players of Large Molecule Drug Substance CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Large Molecule Drug Substance CDMO Breakdown Data by Type
4.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Type (2021–2026)
4.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (2027–2032)
5 Large Molecule Drug Substance CDMO Breakdown Data by Application
5.1 Global Large Molecule Drug Substance CDMO Historic Market Size by Application (2021–2026)
5.2 Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Large Molecule Drug Substance CDMO Market Size (2021–2032)
6.2 North America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
6.4 North America Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Large Molecule Drug Substance CDMO Market Size (2021–2032)
7.2 Europe Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
7.4 Europe Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Large Molecule Drug Substance CDMO Market Size (2021–2032)
8.2 Asia-Pacific Large Molecule Drug Substance CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Large Molecule Drug Substance CDMO Market Size (2021–2032)
9.2 Latin America Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
9.4 Latin America Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Large Molecule Drug Substance CDMO Market Size (2021–2032)
10.2 Middle East & Africa Large Molecule Drug Substance CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Large Molecule Drug Substance CDMO Introduction
11.1.4 Lonza Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Large Molecule Drug Substance CDMO Introduction
11.2.4 Catalent Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Large Molecule Drug Substance CDMO Introduction
11.3.4 Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Large Molecule Drug Substance CDMO Introduction
11.5.4 Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi Biologics
11.6.1 WuXi Biologics Company Details
11.6.2 WuXi Biologics Business Overview
11.6.3 WuXi Biologics Large Molecule Drug Substance CDMO Introduction
11.6.4 WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.6.5 WuXi Biologics Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Large Molecule Drug Substance CDMO Introduction
11.7.4 Recipharm Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Large Molecule Drug Substance CDMO Introduction
11.8.4 Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Large Molecule Drug Substance CDMO Introduction
11.9.4 AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Large Molecule Drug Substance CDMO Introduction
11.10.4 Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Large Molecule Drug Substance CDMO Introduction
11.11.4 KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Large Molecule Drug Substance CDMO Introduction
11.12.4 Siegfried Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Large Molecule Drug Substance CDMO Introduction
11.13.4 Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Large Molecule Drug Substance CDMO Introduction
11.14.4 GenScript Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Large Molecule Drug Substance CDMO Introduction
11.15.4 ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Large Molecule Drug Substance CDMO Introduction
11.16.4 Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Introduction
11.17.4 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (2021–2026)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Cell and Gene Therapies
Table 3. Key Players of Antibodies
Table 4. Key Players of Vaccines
Table 5. Key Players of Other
Table 6. Global Large Molecule Drug Substance CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Large Molecule Drug Substance CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2021–2026
Table 9. Global Large Molecule Drug Substance CDMO Market Share by Region (2021–2026)
Table 10. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Large Molecule Drug Substance CDMO Market Share by Region (2027–2032)
Table 12. Large Molecule Drug Substance CDMO Market Trends
Table 13. Large Molecule Drug Substance CDMO Market Drivers
Table 14. Large Molecule Drug Substance CDMO Market Challenges
Table 15. Large Molecule Drug Substance CDMO Market Restraints
Table 16. Global Large Molecule Drug Substance CDMO Revenue by Players (US$ Million), 2021–2026
Table 17. Global Large Molecule Drug Substance CDMO Market Share by Players (2021–2026)
Table 18. Global Top Large Molecule Drug Substance CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Large Molecule Drug Substance CDMO Revenue, 2025
Table 19. Ranking of Global Top Large Molecule Drug Substance CDMO Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Large Molecule Drug Substance CDMO Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Large Molecule Drug Substance CDMO, Headquarters and Area Served
Table 22. Global Key Players of Large Molecule Drug Substance CDMO, Products and Applications
Table 23. Global Key Players of Large Molecule Drug Substance CDMO, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Large Molecule Drug Substance CDMO Market Size by Type (US$ Million), 2021–2026
Table 26. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2021–2026)
Table 27. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2027–2032)
Table 29. Global Large Molecule Drug Substance CDMO Market Size by Application (US$ Million), 2021–2026
Table 30. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2021–2026)
Table 31. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2027–2032)
Table 33. North America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 35. North America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Large Molecule Drug Substance CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 48. Lonza Company Details
Table 49. Lonza Business Overview
Table 50. Lonza Large Molecule Drug Substance CDMO Product
Table 51. Lonza Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 52. Lonza Recent Development
Table 53. Catalent Company Details
Table 54. Catalent Business Overview
Table 55. Catalent Large Molecule Drug Substance CDMO Product
Table 56. Catalent Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 57. Catalent Recent Development
Table 58. Samsung Biologics Company Details
Table 59. Samsung Biologics Business Overview
Table 60. Samsung Biologics Large Molecule Drug Substance CDMO Product
Table 61. Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 62. Samsung Biologics Recent Development
Table 63. FUJIFILM Diosynth Biotechnologies Company Details
Table 64. FUJIFILM Diosynth Biotechnologies Business Overview
Table 65. FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Product
Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 67. FUJIFILM Diosynth Biotechnologies Recent Development
Table 68. Boehringer Ingelheim Company Details
Table 69. Boehringer Ingelheim Business Overview
Table 70. Boehringer Ingelheim Large Molecule Drug Substance CDMO Product
Table 71. Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 72. Boehringer Ingelheim Recent Development
Table 73. WuXi Biologics Company Details
Table 74. WuXi Biologics Business Overview
Table 75. WuXi Biologics Large Molecule Drug Substance CDMO Product
Table 76. WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 77. WuXi Biologics Recent Development
Table 78. Recipharm Company Details
Table 79. Recipharm Business Overview
Table 80. Recipharm Large Molecule Drug Substance CDMO Product
Table 81. Recipharm Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 82. Recipharm Recent Development
Table 83. Thermo Fisher Scientific Company Details
Table 84. Thermo Fisher Scientific Business Overview
Table 85. Thermo Fisher Scientific Large Molecule Drug Substance CDMO Product
Table 86. Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 87. Thermo Fisher Scientific Recent Development
Table 88. AGC Biologics Company Details
Table 89. AGC Biologics Business Overview
Table 90. AGC Biologics Large Molecule Drug Substance CDMO Product
Table 91. AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 92. AGC Biologics Recent Development
Table 93. Rentschler Biopharma Company Details
Table 94. Rentschler Biopharma Business Overview
Table 95. Rentschler Biopharma Large Molecule Drug Substance CDMO Product
Table 96. Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 97. Rentschler Biopharma Recent Development
Table 98. KBI Biopharma Company Details
Table 99. KBI Biopharma Business Overview
Table 100. KBI Biopharma Large Molecule Drug Substance CDMO Product
Table 101. KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 102. KBI Biopharma Recent Development
Table 103. Siegfried Company Details
Table 104. Siegfried Business Overview
Table 105. Siegfried Large Molecule Drug Substance CDMO Product
Table 106. Siegfried Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 107. Siegfried Recent Development
Table 108. Aenova Group Company Details
Table 109. Aenova Group Business Overview
Table 110. Aenova Group Large Molecule Drug Substance CDMO Product
Table 111. Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 112. Aenova Group Recent Development
Table 113. GenScript Company Details
Table 114. GenScript Business Overview
Table 115. GenScript Large Molecule Drug Substance CDMO Product
Table 116. GenScript Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 117. GenScript Recent Development
Table 118. ProBioGen Company Details
Table 119. ProBioGen Business Overview
Table 120. ProBioGen Large Molecule Drug Substance CDMO Product
Table 121. ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 122. ProBioGen Recent Development
Table 123. Northway Biotech Company Details
Table 124. Northway Biotech Business Overview
Table 125. Northway Biotech Large Molecule Drug Substance CDMO Product
Table 126. Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 127. Northway Biotech Recent Development
Table 128. 3P Biopharmaceuticals Company Details
Table 129. 3P Biopharmaceuticals Business Overview
Table 130. 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Product
Table 131. 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 132. 3P Biopharmaceuticals Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Large Molecule Drug Substance CDMO Picture
Figure 2. Global Large Molecule Drug Substance CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Large Molecule Drug Substance CDMO Market Share by Type: 2025 vs 2032
Figure 4. Cell and Gene Therapies Features
Figure 5. Antibodies Features
Figure 6. Vaccines Features
Figure 7. Other Features
Figure 8. Global Large Molecule Drug Substance CDMO Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Large Molecule Drug Substance CDMO Market Share by Application: 2025 vs 2032
Figure 10. SMBs Case Studies
Figure 11. Large Companies Case Studies
Figure 12. Large Molecule Drug Substance CDMO Report Years Considered
Figure 13. Global Large Molecule Drug Substance CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Large Molecule Drug Substance CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Large Molecule Drug Substance CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global Large Molecule Drug Substance CDMO Market Share by Players in 2025
Figure 17. Global Large Molecule Drug Substance CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Large Molecule Drug Substance CDMO Revenue in 2025
Figure 19. North America Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 21. United States Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 25. Germany Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Large Molecule Drug Substance CDMO Market Share by Region (2021–2032)
Figure 33. China Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 41. Mexico Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 45. Israel Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Lonza Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 49. Catalent Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 50. Samsung Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 52. Boehringer Ingelheim Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 53. WuXi Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 54. Recipharm Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 56. AGC Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 57. Rentschler Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 58. KBI Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 59. Siegfried Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 60. Aenova Group Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 61. GenScript Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 62. ProBioGen Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 63. Northway Biotech Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Large Molecule Drug Substance CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Cell and Gene Therapies
Table 3. Key Players of Antibodies
Table 4. Key Players of Vaccines
Table 5. Key Players of Other
Table 6. Global Large Molecule Drug Substance CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Large Molecule Drug Substance CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2021–2026
Table 9. Global Large Molecule Drug Substance CDMO Market Share by Region (2021–2026)
Table 10. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Large Molecule Drug Substance CDMO Market Share by Region (2027–2032)
Table 12. Large Molecule Drug Substance CDMO Market Trends
Table 13. Large Molecule Drug Substance CDMO Market Drivers
Table 14. Large Molecule Drug Substance CDMO Market Challenges
Table 15. Large Molecule Drug Substance CDMO Market Restraints
Table 16. Global Large Molecule Drug Substance CDMO Revenue by Players (US$ Million), 2021–2026
Table 17. Global Large Molecule Drug Substance CDMO Market Share by Players (2021–2026)
Table 18. Global Top Large Molecule Drug Substance CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Large Molecule Drug Substance CDMO Revenue, 2025
Table 19. Ranking of Global Top Large Molecule Drug Substance CDMO Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Large Molecule Drug Substance CDMO Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Large Molecule Drug Substance CDMO, Headquarters and Area Served
Table 22. Global Key Players of Large Molecule Drug Substance CDMO, Products and Applications
Table 23. Global Key Players of Large Molecule Drug Substance CDMO, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Large Molecule Drug Substance CDMO Market Size by Type (US$ Million), 2021–2026
Table 26. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2021–2026)
Table 27. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Large Molecule Drug Substance CDMO Revenue Market Share by Type (2027–2032)
Table 29. Global Large Molecule Drug Substance CDMO Market Size by Application (US$ Million), 2021–2026
Table 30. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2021–2026)
Table 31. Global Large Molecule Drug Substance CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Large Molecule Drug Substance CDMO Revenue Market Share by Application (2027–2032)
Table 33. North America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 35. North America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Large Molecule Drug Substance CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Large Molecule Drug Substance CDMO Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Large Molecule Drug Substance CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Large Molecule Drug Substance CDMO Market Size by Country (US$ Million), 2027–2032
Table 48. Lonza Company Details
Table 49. Lonza Business Overview
Table 50. Lonza Large Molecule Drug Substance CDMO Product
Table 51. Lonza Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 52. Lonza Recent Development
Table 53. Catalent Company Details
Table 54. Catalent Business Overview
Table 55. Catalent Large Molecule Drug Substance CDMO Product
Table 56. Catalent Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 57. Catalent Recent Development
Table 58. Samsung Biologics Company Details
Table 59. Samsung Biologics Business Overview
Table 60. Samsung Biologics Large Molecule Drug Substance CDMO Product
Table 61. Samsung Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 62. Samsung Biologics Recent Development
Table 63. FUJIFILM Diosynth Biotechnologies Company Details
Table 64. FUJIFILM Diosynth Biotechnologies Business Overview
Table 65. FUJIFILM Diosynth Biotechnologies Large Molecule Drug Substance CDMO Product
Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 67. FUJIFILM Diosynth Biotechnologies Recent Development
Table 68. Boehringer Ingelheim Company Details
Table 69. Boehringer Ingelheim Business Overview
Table 70. Boehringer Ingelheim Large Molecule Drug Substance CDMO Product
Table 71. Boehringer Ingelheim Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 72. Boehringer Ingelheim Recent Development
Table 73. WuXi Biologics Company Details
Table 74. WuXi Biologics Business Overview
Table 75. WuXi Biologics Large Molecule Drug Substance CDMO Product
Table 76. WuXi Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 77. WuXi Biologics Recent Development
Table 78. Recipharm Company Details
Table 79. Recipharm Business Overview
Table 80. Recipharm Large Molecule Drug Substance CDMO Product
Table 81. Recipharm Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 82. Recipharm Recent Development
Table 83. Thermo Fisher Scientific Company Details
Table 84. Thermo Fisher Scientific Business Overview
Table 85. Thermo Fisher Scientific Large Molecule Drug Substance CDMO Product
Table 86. Thermo Fisher Scientific Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 87. Thermo Fisher Scientific Recent Development
Table 88. AGC Biologics Company Details
Table 89. AGC Biologics Business Overview
Table 90. AGC Biologics Large Molecule Drug Substance CDMO Product
Table 91. AGC Biologics Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 92. AGC Biologics Recent Development
Table 93. Rentschler Biopharma Company Details
Table 94. Rentschler Biopharma Business Overview
Table 95. Rentschler Biopharma Large Molecule Drug Substance CDMO Product
Table 96. Rentschler Biopharma Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 97. Rentschler Biopharma Recent Development
Table 98. KBI Biopharma Company Details
Table 99. KBI Biopharma Business Overview
Table 100. KBI Biopharma Large Molecule Drug Substance CDMO Product
Table 101. KBI Biopharma Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 102. KBI Biopharma Recent Development
Table 103. Siegfried Company Details
Table 104. Siegfried Business Overview
Table 105. Siegfried Large Molecule Drug Substance CDMO Product
Table 106. Siegfried Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 107. Siegfried Recent Development
Table 108. Aenova Group Company Details
Table 109. Aenova Group Business Overview
Table 110. Aenova Group Large Molecule Drug Substance CDMO Product
Table 111. Aenova Group Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 112. Aenova Group Recent Development
Table 113. GenScript Company Details
Table 114. GenScript Business Overview
Table 115. GenScript Large Molecule Drug Substance CDMO Product
Table 116. GenScript Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 117. GenScript Recent Development
Table 118. ProBioGen Company Details
Table 119. ProBioGen Business Overview
Table 120. ProBioGen Large Molecule Drug Substance CDMO Product
Table 121. ProBioGen Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 122. ProBioGen Recent Development
Table 123. Northway Biotech Company Details
Table 124. Northway Biotech Business Overview
Table 125. Northway Biotech Large Molecule Drug Substance CDMO Product
Table 126. Northway Biotech Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 127. Northway Biotech Recent Development
Table 128. 3P Biopharmaceuticals Company Details
Table 129. 3P Biopharmaceuticals Business Overview
Table 130. 3P Biopharmaceuticals Large Molecule Drug Substance CDMO Product
Table 131. 3P Biopharmaceuticals Revenue in Large Molecule Drug Substance CDMO Business (US$ Million), 2021–2026
Table 132. 3P Biopharmaceuticals Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Large Molecule Drug Substance CDMO Picture
Figure 2. Global Large Molecule Drug Substance CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Large Molecule Drug Substance CDMO Market Share by Type: 2025 vs 2032
Figure 4. Cell and Gene Therapies Features
Figure 5. Antibodies Features
Figure 6. Vaccines Features
Figure 7. Other Features
Figure 8. Global Large Molecule Drug Substance CDMO Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Large Molecule Drug Substance CDMO Market Share by Application: 2025 vs 2032
Figure 10. SMBs Case Studies
Figure 11. Large Companies Case Studies
Figure 12. Large Molecule Drug Substance CDMO Report Years Considered
Figure 13. Global Large Molecule Drug Substance CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Large Molecule Drug Substance CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Large Molecule Drug Substance CDMO Market Share by Region: 2025 vs 2032
Figure 16. Global Large Molecule Drug Substance CDMO Market Share by Players in 2025
Figure 17. Global Large Molecule Drug Substance CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Large Molecule Drug Substance CDMO Revenue in 2025
Figure 19. North America Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 21. United States Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 25. Germany Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Large Molecule Drug Substance CDMO Market Share by Region (2021–2032)
Figure 33. China Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 41. Mexico Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Large Molecule Drug Substance CDMO Market Share by Country (2021–2032)
Figure 45. Israel Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Large Molecule Drug Substance CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Lonza Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 49. Catalent Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 50. Samsung Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 52. Boehringer Ingelheim Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 53. WuXi Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 54. Recipharm Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 56. AGC Biologics Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 57. Rentschler Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 58. KBI Biopharma Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 59. Siegfried Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 60. Aenova Group Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 61. GenScript Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 62. ProBioGen Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 63. Northway Biotech Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Large Molecule Drug Substance CDMO Business (2021–2026)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232